Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Santen Pharmaceutical Co ( (JP:4536) ) is now available.
Santen Pharmaceutical Co., Ltd. announced the status of its share buyback program, having repurchased 3,071,200 common shares for a total of 4,765,731,250 yen between October 1 and October 31, 2025. This buyback is part of a broader initiative approved by the Board of Directors to repurchase up to 19,800,000 shares, representing 5.8% of the total outstanding shares, with a maximum budget of 35 billion yen, aimed at enhancing shareholder value.
The most recent analyst rating on (JP:4536) stock is a Hold with a Yen1688.00 price target. To see the full list of analyst forecasts on Santen Pharmaceutical Co stock, see the JP:4536 Stock Forecast page.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a specialized company dedicated to eye health, providing products and services to patients, consumers, and medical professionals worldwide. With over 130 years of experience, Santen focuses on the research, development, manufacturing, and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries.
Average Trading Volume: 1,508,075
Technical Sentiment Signal: Hold
Current Market Cap: Yen515.5B
See more data about 4536 stock on TipRanks’ Stock Analysis page.